Cellectis

Senior Director, Medical Affairs

Cellectis  •  New York (Hybrid)  •  3 months ago
Apply
AI can make mistakes so check important info. Chat history is never stored.

Job Description

Location: New York, NY (Hybrid)
Company: Cellectis
Department: Clinical Development

Cellectis is seeking a highly experienced Senior Director, Medical Affairs to help shape and operationalize the company’s medical affairs strategy across its clinical‑stage portfolio. Reporting to the Chief Medical Officer, this leader will elevate Cellectis’ scientific presence, support pipeline advancement, and ensure medical excellence in evidence generation, scientific communications, and external engagement.

This role is ideal for a medical affairs leader with strong immuno‑oncology expertise, strategic agility, and a passion for patient‑centered innovation.

Key Responsibilities

  • Partner with the CMO to develop and execute Cellectis’ medical affairs strategy.
  • Build and manage critical medical affairs capabilities, including medical strategy, medical communications, publications, and scientific engagement.
  • Provide expert scientific and medical insights across immuno‑oncology programs.
  • Lead engagement with key opinion leaders, investigators, and scientific experts.
  • Represent Cellectis at scientific meetings, advisory boards, and congresses.
  • Drive creation of scientific platforms and data‑driven communication strategies.
  • Oversee development of medical information, publications, and internal scientific education.
  • Identify and address data gaps through evidence‑generation initiatives.
  • Support clinical development and early‑access programs with medical expertise.
  • Integrate patient insights into medical and clinical strategies.
  • Partner cross‑functionally with clinical development, regulatory and communications affairs to ensure alignment and shared decision‑making.
  • Establish governance processes, operational metrics, and reporting frameworks.
  • Promote a culture of scientific rigor, compliance, and patient focus.

Education and Experience

  • Pharm D or MD experience in Hematology / Oncology --
  • 15+ years of medical affairs and/or clinical development experience in the biopharmaceutical industry.
  • Demonstrated experience engaging KOLs, TA experts, payors and patient advocacy organizations.
  • Experience in drug development and/or clinical practice; demonstrated knowledge of competitive landscape, trends, and physician practices.
  • Skilled at presenting clinical and non-clinical data to external audiences and management team(s)
  • Clinical development experience highly preferred.

Core Competencies

  • Excellent clinical judgment and decision‑making skills.
  • Strong interpersonal and communication skills, with the ability to influence cross‑functional teams.
  • Demonstrated ability to build strong partnerships with investigators, KOLs, and internal stakeholders.
  • Proven ability to lead cross‑functional teams in a matrixed environment.
  • Mission‑driven leader with a passion for improving patient outcomes.
  • Comfortable in a fast‑paced, innovative biotech environment.
  • Ability to travel up to 50-60% of time

Compensation Range: $175-225k

Cellectis

About Cellectis

Cellectis is a global clinical-stage biopharmaceutical company. Pioneers and innovators in our field, our mission is to develop innovative treatments for patients with unmet medical needs.

With 25 years of expertise, we have the best-in-class gene editing platform focusing on immuno-oncology, and gene therapy. Through our efficient and precise TALEN® technology, we create allogeneic CAR-T cells capable of recognizing and combating cancer cells.

Today, our two* clinical programs target patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma (NHL).

We are fully integrated and a leader in end-to-end gene editing, allogeneic CAR T-cell companies. With our in-house manufacturing, we control our gene and cell therapy process from start to finish with starting materials produced in Paris (France) and CAR-T therapy products created in Raleigh, NC.

We also have several ongoing strong collaborations, based on our TALEN® technology, with leading cell & gene therapy companies, including our recent partnership with AstraZeneca, to develop new product candidates in oncology, immunology, and treatment of rare diseases.

At Cellectis, we are committed to a cure.

Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).

To find out more about us, visit our website: www.cellectis.com. To learn more about our community guidelines, visit: http://www.cellectis.com/en/social-media-guidelines/

Follow our other social media account on X.

(*) On November 4, 2024, Cellectis decided to focus its current development efforts on the BALLI-01 and NATHALI-01 studies and therefore to deprioritize the development of UCART123.

TALEN® is a registered trademark owned by the Cellectis Group.

Industry
Biotech & Life Sciences
Company Size
201-500 employees
Headquarters
Paris, FR
Year Founded
1999
Social Media